Methergine is said to be the only FDA-approved oral uterotonic and is a preferred oral agent in the management of PPH
Pharma Major Lupin Limited and its US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) have announced the re-introduction of Methergine (methylergonovine maleate) Oral Tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH).
Methergine is said to be the only FDA-approved oral uterotonic and is a preferred oral agent in the management of PPH , according to guidelines issued by the American Congress of Obstetricians and Gynecologists (ACOG) . More than half of all maternal deaths occur within 24 hours of birth, most commonly from excessive bleeding , and rates of maternal morality continue to rise in the US where PPH is a leading cause of pregnancy complications .
"The re-introduction of Methergine is a proud moment for Lupin, but also an important moment for expectant mothers across the country to feel confident in care options," said Mr Paul McGarty, president, Lupin Pharmaceuticals. "With Methergine, Lupin is making a significant investment to help improve the management of PPH, providing professional medical education, leveraging its specialized sales force to drive better awareness and access to care, and ensuring a more stable supply of this essential medicine."
"Postpartum hemorrhage (PPH) is one of the most preventable causes of maternal mortality and it should be better managed in pursuit of improved patient care," said David B. Schwartz, MD, FACOG, independent OBGYN and ACOG fellow. "I commend Lupin for spotlighting this public health issue and making an investment in treatment, education and awareness of PPH."
A semi-synthetic ergot alkaloid, Methergine is indicated for routine management of uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta, and for control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder.